Exelixis Announces Quality-Adjusted Survival Benefit Demonstrated in Analysis of Phase 3 CheckMate -9ER Trial of CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) in Patients with Previously Untreated Advanced Renal Cell CarcinomaBusiness Wire • 06/04/21
Exelixis Announces Consistent Efficacy Benefits Across Subgroups of Phase 3 CheckMate -9ER Trial of CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as a First-line Treatment for Patients with Advanced Renal Cell CarcinomaBusiness Wire • 06/04/21
Exelixis Announces Positive Phase 2 Results for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma at ASCO 2021Business Wire • 06/04/21
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in JuneBusiness Wire • 05/26/21
Exelixis (EXEL) Reports Encouraging Data From Prostate Cancer StudyZacks Investment Research • 05/25/21
Exelixis' Cabometyx, Roche's Tecentriq Combo Achieves 27% ORR in High-Risk Prostate Cancer PatientsBenzinga • 05/25/21
Exelixis Announces Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patients with Metastatic Castration-Resistant Prostate CancerBusiness Wire • 05/24/21
Exelixis (EXEL) CEO Mike Morrissey on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/07/21
Exelixis Announces First Quarter 2021 Financial Results and Provides Corporate UpdateBusiness Wire • 05/06/21
Exelixis Expands its Biotherapeutics Portfolio with Acquisition of GamaMabs Pharma's First-in-Class Humanized Antibody Program Against a Novel Oncology TargetBusiness Wire • 05/04/21
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in MayBusiness Wire • 04/27/21
Exelixis to Release First Quarter 2021 Financial Results on Thursday, May 6, 2021Business Wire • 04/22/21
Exelixis Announces U.S. FDA Accepts Investigational New Drug Application for XB002 in Patients with Advanced Solid TumorsBusiness Wire • 04/05/21
Exelixis' Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as First-Line Treatment for Patients with Advanced Renal Cell CarcinomaBusiness Wire • 03/31/21